



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

5 July 2021

Dear Shareholders,

Election of Means of Receipt and Language of Corporate Communications

Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the articles of association of PuraPharm Corporation Limited (the “**Company**”), the Company will make available the following options for you to elect for means of receipt and language of future corporate communications (the “**Corporate Communications**”) of the Company, namely any document(s) issued or to be issued by the Company for the information or action of any holders of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form, in the following manner:

- (1) to read all future Corporate Communications published on the Company’s website at <https://www.purapharm.com/> and the website of Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk (the “**Website Version**”) in place of receiving printed copies, and receive a printed notification letter of the publication of the Corporate Communications on the Company’s website and the website of Hong Kong Exchanges and Clearing Limited; or
- (2) to receive the printed English version of all future Corporate Communications only; or
- (3) to receive the printed Chinese version of all future Corporate Communications only; or
- (4) to receive both the printed English and Chinese versions of all future Corporate Communications.

In support of environmental protection and for better operational efficiency, the Company recommends you to select the Website Version option. To make your election, please mark “X” in the appropriate box on the enclosed Reply Form, sign and return it to the Company’s Hong Kong share registrar (the “**Hong Kong Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong. If you post your Reply Form in Hong Kong, you may use the mailing label in the Reply Form and need not affix a stamp when returning your Reply Form. Otherwise, please affix an appropriate stamp.

If the Company does not receive the enclosed Reply Form duly completed and signed or a response indicating the objection from you by 4 August 2021, you will be deemed to have consented to receiving Website Version of all future Corporate Communications and a printed notification letter of the publication of the Corporate Communications will be sent to you in the future.

You are entitled at any time by providing reasonable notice in writing to the Company c/o the Hong Kong Share Registrar or by sending an email to purapharm.ecom@computershare.com.hk to change the means of receipt and/or choice of language of the Corporate Communications. Even if you have chosen (or are deemed to have consented) to receive the Website Version of all future Corporate Communications, and if for any reasons, you have difficulty in receiving or gaining access to Website Version of the Corporate Communications, the Hong Kong Share Registrar will, upon your request in writing or by e-mail, send the Corporate Communications to you in printed form free of charge.

Please note that (a) the printed copies of the English and Chinese versions of all future Corporate Communications will be available from the Company c/o the Hong Kong Share Registrar upon request; and (b) the English and Chinese versions of all future Corporate Communications will also be available on the Company’s website at <https://www.purapharm.com/> and the website of Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk.

Should you have any queries in relation to this letter, please call the hotline of the Hong Kong Share Registrar at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding public holidays).

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and executive Director